Coronary Care Unit, Concord Hospital, Sydney, Australia.
JACC Cardiovasc Interv. 2009 Jan;2(1):26-33. doi: 10.1016/j.jcin.2008.09.010.
We investigated the relative benefit of reperfusion strategies in renal dysfunction and ST-segment elevation/left bundle branch block (STE/LBBB).
Few data are available informing the treatment of STE myocardial infarction in the presence of renal dysfunction.
Patients (N = 12,532) from the GRACE (Global Registry of Acute Coronary Events) presenting with STE/LBBB were stratified by renal function and receipt of fibrinolysis, primary percutaneous coronary intervention (PCI), or neither.
As renal function declined, hospital mortality increased and reperfusion decreased (both p < 0.001). Compared with no reperfusion, primary PCI was associated with lower hospital mortality in patients with normal renal function (1.9% vs. 3.7%, p = 0.001, adjusted) but no reduction in those with renal dysfunction (14% vs. 15% for glomerular filtration rate [GFR] 30 to 59 ml/min/1.73 m(2); 29% vs. 32% for GFR <30 ml/min/1.73 m(2)). Fibrinolysis was not associated with lower hospital mortality for normal (3.1% vs. 3.7%, p = NS) or low renal function (32% vs. 32%, p = NS) and with higher mortality with moderate renal dysfunction (adjusted odds ratio: 1.35, 95% confidence interval: 1.01 to 1.80). Primary PCI was associated with increased hospital bleeding and fibrinolysis with increased stroke in all patients. Among hospital survivors, primary PCI, but not fibrinolysis, was associated with lower mortality for moderate dysfunction. Both reperfusion strategies were associated with higher mortality for severe dysfunction.
In STE/LBBB and renal dysfunction, mortality rates are high and reperfusion rates are lower. In moderate renal dysfunction, primary PCI is associated with mortality reduction at 6 months. Outcomes remain poor with severe renal dysfunction, despite receipt of reperfusion therapy.
我们研究了肾功能障碍和 ST 段抬高/左束支传导阻滞(STE/LBBB)患者再灌注策略的相对益处。
关于肾功能障碍患者 STE 心肌梗死的治疗,目前仅有少量数据可用。
GRACE(全球急性冠状动脉事件登记处)登记的 12532 例 STE/LBBB 患者按肾功能和是否接受溶栓、直接经皮冠状动脉介入治疗(PCI)或两者均未接受进行分层。
随着肾功能下降,住院死亡率增加,再灌注治疗减少(均 P<0.001)。与未再灌注治疗相比,在肾功能正常的患者中,直接 PCI 与较低的住院死亡率相关(1.9% vs. 3.7%,P=0.001,校正),但在肾功能障碍患者中无降低(肾小球滤过率 [GFR] 30-59 ml/min/1.73 m2 者为 14% vs. 15%;GFR<30 ml/min/1.73 m2 者为 29% vs. 32%)。溶栓治疗与正常(3.1% vs. 3.7%,P=NS)或低肾功能(32% vs. 32%,P=NS)患者的住院死亡率降低无关,与中度肾功能障碍患者死亡率升高相关(校正比值比:1.35,95%置信区间:1.01 至 1.80)。直接 PCI 与所有患者的住院出血增加相关,而溶栓治疗与中风增加相关。在住院存活者中,直接 PCI 与中度肾功能障碍患者的死亡率降低相关,但溶栓治疗无此相关性。两种再灌注策略与严重肾功能障碍患者的死亡率升高均相关。
在 STE/LBBB 和肾功能障碍患者中,死亡率高,再灌注率低。在中度肾功能障碍患者中,直接 PCI 与 6 个月时的死亡率降低相关。尽管接受了再灌注治疗,严重肾功能障碍患者的预后仍较差。